도그우드 테라퓨틱스(DWTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.15 (+8.59%), 시가총액 $0.06B, 52주 범위 $1.34 ~ $7.91.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat
도그우드 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
도그우드 테라퓨틱스의 현재 주가는 $2.15 (+8.59%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
도그우드 테라퓨틱스의 시가총액은 약 $0.06B입니다.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a